company background image
LIVN

LivaNovaNasdaqGS:LIVN Stock Report

Last Price

US$83.17

Market Cap

US$4.4b

7D

-1.8%

1Y

29.0%

Updated

19 Jan, 2022

Data

Company Financials +
LIVN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

LIVN Stock Overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.

LivaNova Competitors

Abbott Laboratories

NYSE:ABT

US$216.2b

Medtronic

NYSE:MDT

US$144.9b

Edwards Lifesciences

NYSE:EW

US$72.5b

Boston Scientific

NYSE:BSX

US$62.8b

Price History & Performance

Summary of all time highs, changes and price drops for LivaNova
Historical stock prices
Current Share PriceUS$83.17
52 Week HighUS$93.89
52 Week LowUS$61.76
Beta0.89
1 Month Change3.64%
3 Month Change1.94%
1 Year Change29.03%
3 Year Change-6.80%
5 Year Change72.88%
Change since IPO593.08%

Recent News & Updates

Dec 29
At US$87.75, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

At US$87.75, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

LivaNova PLC ( NASDAQ:LIVN ), is not the largest company out there, but it saw a double-digit share price rise of over...

Nov 29
Does LivaNova (NASDAQ:LIVN) Have A Healthy Balance Sheet?

Does LivaNova (NASDAQ:LIVN) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Nov 16

Milan Court Decision Does Not Change LivaNova Bullish Story

The courts in Milan ruled that LivaNova would be liable for $519 million in damages in connection with a former parent company from Sorin with which it merged years ago. While they appeal the ruling, it really changes nothing in the LivaNova story which remains fully about the treatment resistant depression opportunity. Other parts of the portfolio, even cardiovascular, are doing better than expected too thanks to a recovery in procedure volumes and end-of-service implant replacements. With the recovery, they are getting closer to profitability even with the current business constitution, but DTD remains the main catalyst for driving returns.

Shareholder Returns

LIVNUS Medical EquipmentUS Market
7D-1.8%-4.8%-4.6%
1Y29.0%-0.4%7.7%

Return vs Industry: LIVN exceeded the US Medical Equipment industry which returned 0.8% over the past year.

Return vs Market: LIVN exceeded the US Market which returned 10.2% over the past year.

Price Volatility

Is LIVN's price volatile compared to industry and market?
LIVN volatility
LIVN Average Weekly Movement6.0%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: LIVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: LIVN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19874,000Damien McDonaldhttps://www.livanova.com

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

LivaNova Fundamentals Summary

How do LivaNova's earnings and revenue compare to its market cap?
LIVN fundamental statistics
Market CapUS$4.43b
Earnings (TTM)-US$406.58m
Revenue (TTM)US$1.03b

4.3x

P/S Ratio

-10.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LIVN income statement (TTM)
RevenueUS$1.03b
Cost of RevenueUS$351.67m
Gross ProfitUS$683.19m
ExpensesUS$1.09b
Earnings-US$406.58m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 23, 2022

Earnings per share (EPS)-7.64
Gross Margin66.02%
Net Profit Margin-39.29%
Debt/Equity Ratio18.2%

How did LIVN perform over the long term?

See historical performance and comparison

Valuation

Is LivaNova undervalued compared to its fair value and its price relative to the market?

24.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LIVN ($83.17) is trading below our estimate of fair value ($110.22)

Significantly Below Fair Value: LIVN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LIVN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: LIVN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LIVN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LIVN is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (3.5x).


Future Growth

How is LivaNova forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

61.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LIVN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: LIVN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LIVN's is expected to become profitable in the next 3 years.

Revenue vs Market: LIVN's revenue (5.6% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: LIVN's revenue (5.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LIVN's Return on Equity is forecast to be low in 3 years time (10.8%).


Past Performance

How has LivaNova performed over the past 5 years?

-61.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LIVN is currently unprofitable.

Growing Profit Margin: LIVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LIVN is unprofitable, and losses have increased over the past 5 years at a rate of 61.8% per year.

Accelerating Growth: Unable to compare LIVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LIVN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: LIVN has a negative Return on Equity (-30.98%), as it is currently unprofitable.


Financial Health

How is LivaNova's financial position?


Financial Position Analysis

Short Term Liabilities: LIVN's short term assets ($646.4M) do not cover its short term liabilities ($658.5M).

Long Term Liabilities: LIVN's short term assets ($646.4M) exceed its long term liabilities ($232.4M).


Debt to Equity History and Analysis

Debt Level: LIVN's net debt to equity ratio (4.3%) is considered satisfactory.

Reducing Debt: LIVN's debt to equity ratio has increased from 8% to 18.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable LIVN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: LIVN is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 29.3% per year.


Dividend

What is LivaNova current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LIVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LIVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LIVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LIVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LIVN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Damien McDonald (56 yo)

5yrs

Tenure

US$6,902,353

Compensation

Mr. Damien McDonald is the Chief Executive Officer and an Executive Director of LivaNova PLC. Since January 1, 2017. Mr. McDonald served as Chief Operating Officer of LivaNova from October 3, 2016 through...


CEO Compensation Analysis

Compensation vs Market: Damien's total compensation ($USD6.90M) is above average for companies of similar size in the US market ($USD5.14M).

Compensation vs Earnings: Damien's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: LIVN's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: LIVN's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LIVN insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.


Top Shareholders

Company Information

LivaNova PLC's employee growth, exchange listings and data sources


Key Information

  • Name: LivaNova PLC
  • Ticker: LIVN
  • Exchange: NasdaqGS
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$4.427b
  • Shares outstanding: 53.23m
  • Website: https://www.livanova.com

Number of Employees


Location

  • LivaNova PLC
  • 20 Eastbourne Terrace
  • Paddington
  • London
  • Greater London
  • W2 6LG
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:30
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.